דנוסומאב
הערות שוליים

1 2 3 4  Steven C Pageau
Denosumab
1 2  McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; et al. (2006). "Denosumab in Postmenopausal Women with Low Bone Mineral Density". N Engl J Med. 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
1 2 3 4  European Medicines Agency Prolia
↑  PRODUCTS
1 2  Denosumab Drugs.com
1 2  Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi:10.1056/NEJMoa0809493. PMID 19671655.
↑  Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and openlabel extension. Lancet Diabetes Endocrinol. 2017; 5:513-523. https://pubmed.ncbi.nlm.nih.gov/28546097/
↑  Singer AJ, Liu J, Yan H, Stad RK, Gandra SR, Yehoshua A. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int. 2021 Dec;32(12):2473-2484.
↑  Lipton, A; Fizazi, K; Stopeck, AT; Henry, DH; Brown, JE; Yardley, DA; Richardson, GE; Siena, S; Maroto, P; Clemens, M; Bilynskyy, B; Charu, V; Beuzeboc, P; Rader, M; Viniegra, M; Saad, F; Ke, C; Braun, A; Jun, S (November 2012). "Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials". EJC (Oxford, England : 1990). 48 (16): 3082–92. doi:10.1016/j.ejca.2012.08.002. PMID 22975218.
↑  Haberfeld, H, ed. (2017). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Prolia-Injektionslösung in einer Fertigspritze. ISBN 978-3-85200-196-8.
↑  Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G, Cao X, Wang P. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2113-22. PMID 24966919; https://pubmed.ncbi.nlm.nih.gov/24966919/
↑  Sundeep Khosla Increasing Options for the Treatment of Osteoporosis
1 2  TNFSF11 TNF superfamily member 11 Homo sapiens (human)
↑  Alison M Boyce Denosumab: An Emerging Therapy in Pediatric Bone Disorders
↑  Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. American Association Of Clinical Endocrinologists/American College Of Endocrinology Clinical Practice Guidelines For The Diagnosis And Treatment Of Postmenopausal Osteoporosis - 2020 Update Executive Summary. Endocr Pract. 2020 May;26(5):564-570. https://pubmed.ncbi.nlm.nih.gov/32427525/
↑  Juliann Schaeffer Injectable Prolia — Osteoporosis Update
↑  Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
↑  F.D.A. Says No to an Amgen Bone Drug
1 2  FDA Approves Denosumab for Osteoporosis
↑  Matthew Perrone FDA clears Amgen's bone-strengthening drug, Prolia
↑  Amgen’s Denosumab Cleared by FDA for Second Indication
↑  Denosumab
| --- | --- |
בקרת זהויות :  BNE: XX5449179 
הבהרה: המידע בוויקיפדיה נועד להעשרה בלבד ואינו מהווה ייעוץ רפואי.